Skip to main content
SpringerLink
Log in

Fecal calprotectin concentration in patients with colorectal carcinoma

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

PURPOSE: The study contained herein was undertaken to investigate fecal calprotectin excretion in a series of patients with colorectal carcinoma and to determine whether the excretion was influenced by localization or stage of the tumor. Furthermore, the effect of surgical treatment on the concentrations was studied. Fecal calprotectin was also compared with plasma concentrations of calprotectin, carcinoembryonic antigen, and C-reactive protein. METHODS: Fecal calprotectin was measured in 119 consecutive patients admitted for treatment of colorectal carcinoma. In 116 (97.5 percent) patients, resectional surgery was performed. Plasma calprotectin was measured in 90 (76 percent) patients, carcinoembryonic antigen in 88 (74 percent) patients, and C-reactive protein in 82 (69 percent) patients. RESULTS: Median fecal calprotectin concentration in the 119 patients was 50 (range, 2-950) mg/l, which was significantly (P<0.0001) higher than in 125 control patients (median, 5.2 mg/l). In 23 patients studied also after resection, the excretion fell greatly. There were no significant differences in fecal calprotectin concentration among patients with different tumor stages. Elevated plasma calprotectin concentrations were found in 67 of 90 (73.3 percent) patients with colorectal carcinoma, compared with elevated fecal calprotectin in 111 of 119 (93.3 percent) patients, and there was no significant correlation between plasma and fecal calprotectin concentrations. Plasma calprotectin concentrations were significantly lower in patients with T1 or T2 tumors than in those with more advanced stages (P=0.0025). CONCLUSION: Measurement of fecal calprotectin may become a diagnostic tool in detecting colorectal carcinoma. The specificity in relation to colorectal carcinoma has not, however, been completely investigated. Both neoplastic and inflammatory conditions may be associated with elevated values; therefore, it is unlikely that calprotectin can predict specific colonic disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fagerhol MK, Dale I, Anderson I. Release and quantitation of leukocyte derived protein (L1). Scand J Haematol 1980;24:393–8.

    Google Scholar 

  2. Fagerhol MK, Anderson KB, Naess-Andresen CF, Brandzaeg P, Dale I. Calprotectin (the L1 leucocyte protein) In: Smith V, Dedman JR, eds. Stimulus response coupling: the role of intracellular calcium binding proteins. Boca Raton: CRC Press, 1990:87–210.

    Google Scholar 

  3. Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes: immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol 1985;84:24–34.

    PubMed  Google Scholar 

  4. Berntzen HB, Fagerhol MK. L1, a major granulocyte protein: isolation of high quantities of its subunits. Scand J Clin Lab Invest 1990;50:769–74.

    PubMed  Google Scholar 

  5. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol 1992;27:793–8.

    PubMed  Google Scholar 

  6. Roseth AG, Kristinsson J, Fagerhol MK,et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073–6.

    PubMed  Google Scholar 

  7. Gilbert JA, Ahlquist D, Mahony DW, Zinsmeister AR, Rubin J, Ellefson RD. Fecal marker variability in colorectal cancer: calprotectinversus hemoglobin. Scand J Gastroenterol 1996;31:1001–6.

    PubMed  Google Scholar 

  8. Hermanek P, Sobin LH. TNM classification of malignant tumours. 4th ed. Berlin: Springer-Verlag, 1992.

    Google Scholar 

  9. Morson BC. Precancerous and early malignant lesions of the large intestine. Br J Surg 1968;55:725–31.

    PubMed  Google Scholar 

  10. Dale I. Plasma levels of the calcium-binding L1 leukocyte protein: standardization of blood collection and evaluation of reference intervals in healthy controls. Scand J Clin Lab Invest 1990;50:837–41.

    PubMed  Google Scholar 

  11. Bormer OP, Nustad K. Selection of monoclonal antibodies for use in an immunometric assay for carcinoembryonic antigen. J Immunol Methods 1990;127:171–8.

    Article  PubMed  Google Scholar 

  12. Meling GI, Rognum TO, Clausen OP,et al. Serum carcinoembryonic antigen in relation to survival, DNA ploidy pattern, and recurrent disease in 406 colorectal carcinoma patients. Scand J Gastroenterol 1992;27:1061–8.

    PubMed  Google Scholar 

  13. Berntzen HB, Fagerhol MK, Ostensen M, Mowinckel P, Hoyeraal HM. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 1991;18:133–8.

    PubMed  Google Scholar 

  14. Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989;16:1416–20.

    PubMed  Google Scholar 

  15. Berntzen HB, Fagerhol MK. L1, a major granulocyte protein: antigenic properties of its subunits. Scand J Clin Lab Invest 1988;48:647–52.

    PubMed  Google Scholar 

  16. Sander J, Fagerhol MK, Bakken JS, Dale I. Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein. Scand J Clin Lab Invest 1984;44:357–62.

    PubMed  Google Scholar 

  17. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009–11.

    Article  PubMed  Google Scholar 

  18. Dale I, Brandtzaeg P. Expression of the epithelial L1 antigen as an immunohistochemical marker of squamous cell carcinoma of the lung. Histopathology 1989;14:493–502.

    PubMed  Google Scholar 

  19. Kijlstra A, Broersma L. Lactoferrin stimulates the production of leucocyte migration inhibitory factor by human peripheral mononuclear leucocytes. Clin Exp Immunol 1984;55:459–64.

    PubMed  Google Scholar 

  20. Saverymuttu SH, Maltby P, Batman P, Joseph AE, Maxwell D. False positive localisation of indium-111 granulocytes in colonic carcinoma. Br J Radiol 1986;59:773–7.

    PubMed  Google Scholar 

  21. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993;34:1357–63.

    PubMed  Google Scholar 

  22. Uchida K, Matsuse R, Tomita S, Sugi K, Saitoh O, Ohshiba S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994;27:259–64.

    Article  PubMed  Google Scholar 

  23. Becker W, Schaffer R, Borner W. Sigmoid carcinoma mimicking an intra-abdominal abscess in an 111Inlabeled white blood cell scan. Eur J Nucl Med 1985;11:283–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Aker University Hospital, Norway

    Arne Røseth M.D., Erling Aadland M.D., Ph.D. & Henning Schjønsby M.D., Ph.D.

  2. Department of Pathology, Aker University Hospital, Norway

    Nils Raknerud M.D., Ph.D.

  3. the Department of Immunology and Transfusion Medicine, Ullevål University Hospital, Norway

    Magne Kr. Fagerhol M.D., Ph.D.

  4. Norwegian Radium Hospital, Oslo, Norway

    Ole P. Børmer M.D., Ph.D.

  5. Department of Surgery, Aker University Hospital, 0514, Oslo, Norway

    Jon Kristinsson M.D. & Knut Nygaard M.D., Ph.D.

Authors
  1. Jon Kristinsson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arne Røseth M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Magne Kr. Fagerhol M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erling Aadland M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henning Schjønsby M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ole P. Børmer M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nils Raknerud M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Knut Nygaard M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Kristinsson, J., Røseth, A., Fagerhol, M.K. et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 41, 316–321 (1998). https://doi.org/10.1007/BF02237485

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02237485

Key words

Search

Navigation